Literature DB >> 1666127

Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease) in a patient with elevated Epstein-Barr virus titers.

E H Harley1.   

Abstract

Sinus histiocytosis with massive lymphadenopathy (SHML) is a newly recognized disorder. The etiology of this disease is unknown. An exaggerated response to an offending agent such as the Epstein-Barr virus or Klebsiella bacteria has been postulated. Its course is usually benign. Cervical adenopathy is seen in 97% of the patients, while 30% of patients have nodal involvement in other sites, and 30% have extranodal involvement. There is a 7% mortality rate that occurs primarily in patients with immunologic defects. Corticosteroids ameliorate the constitutional symptoms, but cyclophosphamide appears to have the most beneficial effect. This article presents the case of a patient with SHML who demonstrated elevated Epstein-Barr virus titers.

Entities:  

Mesh:

Year:  1991        PMID: 1666127      PMCID: PMC2571595     

Source DB:  PubMed          Journal:  J Natl Med Assoc        ISSN: 0027-9684            Impact factor:   1.798


  7 in total

1.  Sinus histiocytosis with massive lymphadenopathy. Report of a case associated with elevated EBV antibody titers.

Authors:  M Lober; W Rawlings; G R Newell; R J Reed
Journal:  Cancer       Date:  1973-08       Impact factor: 6.860

2.  Sinus histiocytosis with massive lymphadenopathy: a pseudolymphomatous benign disorder. Analysis of 34 cases.

Authors:  J Rosai; R F Dorfman
Journal:  Cancer       Date:  1972-11       Impact factor: 6.860

3.  Sinus histiocytosis with massive lymphadenopathy. A newly recognized benign clinicopathological entity.

Authors:  J Rosai; R F Dorfman
Journal:  Arch Pathol       Date:  1969-01

4.  Sinus histiocytosis with massive lymphadenopathy: response to cyclophosphamide therapy.

Authors:  S B Newman; D L Sweet; J W Vardiman
Journal:  Cancer Treat Rep       Date:  1984-06

5.  Sinus histiocytosis with massive lymphadenopathy: fifteen new cases.

Authors:  F Lampert; K Lennert
Journal:  Cancer       Date:  1976-02       Impact factor: 6.860

6.  Sinus histiocytosis with massive cervical lymphadenopathy. Case report and literature review.

Authors:  V G Schweitzer; G D Bobier
Journal:  Ann Otol Rhinol Laryngol       Date:  1986 Jul-Aug       Impact factor: 1.547

7.  Sinus histiocytosis with massive lymphadenopathy. An analysis of 14 deaths occurring in a patient registry.

Authors:  E Foucar; J Rosai; R F Dorfman
Journal:  Cancer       Date:  1984-11-01       Impact factor: 6.860

  7 in total
  6 in total

1.  Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): clinico-pathological study of three cases.

Authors:  Mercedes Bernácer-Borja; Miriam Blanco-Rodríguez; Jose Manuel Sanchez-Granados; Rocío Benitez-Fuentes; Alicia Cazorla-Jimenez; Carmen Rivas-Manga
Journal:  Eur J Pediatr       Date:  2006-04-19       Impact factor: 3.183

2.  Rosai-Dorfman disease: A rare clinico-pathological presentation.

Authors:  Bhushan M Warpe; Shraddha V More
Journal:  Australas Med J       Date:  2014-02-28

3.  Ophthalmic Manifestations of Rosai-Dorfman Disease in Five Patients.

Authors:  Babak Masoomian; Sara E Lally; Jerry A Shields; Carol L Shields
Journal:  J Curr Ophthalmol       Date:  2020-07-04

4.  NRAS Mutations May Be Involved in the Pathogenesis of Cutaneous Rosai Dorfman Disease: A Pilot Study.

Authors:  Kuan-Jou Wu; Shu-Hao Li; Jia-Bin Liao; Chien-Chun Chiou; Chieh-Shan Wu; Chien-Chin Chen
Journal:  Biology (Basel)       Date:  2021-05-02

5.  Rosai dorfman disease of the orbit.

Authors:  Geeta K Vemuganti; Milind N Naik; Santosh G Honavar
Journal:  J Hematol Oncol       Date:  2008-06-28       Impact factor: 17.388

Review 6.  Tracheobronchial Involvement of Rosai-Dorfman Disease: Case Report and Review of the Literature.

Authors:  Louis Boissière; Martine Patey; Olivier Toubas; Juliette Vella-Boucaud; Jeanne-Marie Perotin-Collard; Gaëtan Deslée; Francois Lebargy; Sandra Dury
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.